Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows Pharma to succeed against difficult targets and deliver best-in-class antibody therapeutics.
Download FileAt the 2021 AE&T EU conference, Tracey Mullens, CEO of Abveris, and Brian Walters, CEO of Genovac, joined John Proctor, SVP Antibody Therapeutics, for a discussion about the evolving landscape of antibody therapeutics, the technologies they have turned to address today’s complex targets, and how they are preparing for tomorrow’s challenges.
Learn about accelerating target-to-lead antibody candidate selection with the Beacon platform in this Antibody Engineering & Therapeutics Digital Week 2019 webinar.
Listen to the world’s leading experts on antibody discovery to discuss how we can build a global defensive barrier to find new therapeutic antibodies against the coronavirus and future pathogens.